Tesla's Optimus humanoid robot is central to one of Wall Street's most aggressive bull cases, yet the company has yet to achieve significant commercial deployment, and production timelines remain uncertain. While Wedbush analyst Dan Ives has set a $600 price target on Tesla stock (implying 70% upside from current levels), that optimistic view depends entirely on Optimus scaling to production volumes that have never been publicly demonstrated. The gap between Ives' vision and consensus expectations reveals a fundamental disagreement about whether Tesla can transform from an automaker into a robotics and artificial intelligence platform.

Why Is Optimus Taking So Long to Reach Production?

Tesla's humanoid robot program has faced repeated delays and missed milestones. Elon Musk previously hinted at Optimus 3 production starting in summer 2026, but no announcements have emerged confirming that timeline. JPMorgan Chase now anticipates commercialization in the second half of 2027, a significant delay from earlier expectations. The robot uses technologies borrowed from Tesla's autonomous vehicle program, including computer vision, neural networks, batteries, and electric motors. However, Musk has acknowledged that the initial production ramp will be extremely slow, a candid admission that undercuts the bull case.

Tesla does possess something most robotics startups lack: experience manufacturing complicated machines at enormous scale. Yet that advantage has not translated into faster Optimus deployment. The company is already behind in the autonomous vehicle race, with Alphabet's Waymo leading the way, and the humanoid robot segment has hit another roadblock. For investors betting on Ives' $600 target, this execution risk is substantial.

How Does Optimus Compare to Competitors in the Humanoid Robot Race?

Tesla is not alone in pursuing general-purpose humanoid robots. A competitive landscape has emerged with several companies already demonstrating real-world capabilities. Figure AI, a California-based startup, has already deployed its Figure 03 robot on an active BMW production line, where it loaded more than 90,000 components and accumulated over 1,250 operating hours. Chinese manufacturers have established a substantial lead in production, accounting for more than four out of every five humanoid robot installations worldwide in 2025.

• Figure AI: Demonstrated its Figure 03 robot on active BMW production lines, with the earlier Figure 02 contributing to the production of more than 30,000 vehicles.
• AgiBot: Led the global market with 30.4% of humanoid robot installations in 2025, driven by mass production and an open-source strategy.
• Unitree Robotics: Captured 26.4% of worldwide humanoid installations in 2025 and offers affordable hardware starting at approximately $13,500 for its G1 humanoid.
• UBTech Robotics: Shipped 1,079 full-size humanoids in 2025, targeting industrial work in automotive manufacturing and logistics.
• Boston Dynamics: Is transforming its Atlas humanoid from an experimental platform into a commercially useful manufacturing robot, working with Google DeepMind on AI capabilities.

These competitors are not waiting for Optimus to arrive. They are already shipping units, refining their technology in real-world environments, and building relationships with manufacturers. Tesla's delay gives rivals time to establish market presence and prove economic value before Optimus reaches production.

What Does the Bull Case Actually Require to Work?

Ives' $600 price target rests on three interconnected bets. First, Tesla's Full Self-Driving (FSD) software must graduate into a genuine software subscription franchise with gross margins above 80%, similar to software companies rather than automotive suppliers. Second, the Robotaxi network must scale beyond seven U.S. markets without a serious safety incident. Third, Optimus must ship in volume, with Musk's aspirational targets of 1 million units annually for Optimus 3 and 10 million for Optimus 4.

The first two catalysts show some progress. Paid FSD customers reached nearly 1.5 million globally, with an attach rate above 55% on new North American deliveries. Robotaxi operations have expanded to seven U.S. markets with more than 380,000 miles of unsupervised driving and zero notable incidents. However, Tesla's financial performance in the second quarter of 2026 raises serious questions about whether the company can fund this vision. Operating margin collapsed to 1.4%, free cash flow flipped to negative $1.09 billion, and management now expects 2026 capital expenditure to exceed $25 billion and continue growing for two to three more years.

Why Are Analysts So Divided on Tesla's Future?

The consensus price target of $390.09 implies less than 10% upside from current levels, a stark contrast to Ives' 70% call. This represents the widest debate on Wall Street regarding Tesla's valuation. The broader analyst pool remains cautious, with estimate revisions leaning negative: 18 downward fiscal 2026 earnings per share revisions versus only 7 upward in the trailing 30 days.

Tesla's valuation metrics reflect the market's skepticism. The stock trades at a forward price-to-earnings ratio of 154 and an enterprise value-to-earnings before interest, taxes, depreciation, and amortization ratio of 118, both extremely high multiples. For Ives' thesis to work, investors must believe that Tesla's current financial weakness is temporary and that the company will eventually achieve software-like margins on robotics and autonomous vehicles. The bear case, by contrast, suggests that a 1.4% operating margin, negative free cash flow, and a $25 billion-plus capital expenditure bill climbing higher is too much to underwrite at 154 times forward earnings.

Steps to Evaluate Tesla's Optimus Investment Thesis

• Monitor Quarterly Margins: Track Tesla's operating margin in upcoming quarters to determine whether the company can stabilize profitability while funding Optimus development and Robotaxi expansion.
• Watch for Optimus Production Announcements: Look for official timelines and production volume targets from Tesla, comparing them against JPMorgan Chase's second-half 2027 commercialization estimate.
• Compare Competitive Progress: Assess how quickly Figure AI, AgiBot, and other competitors deploy robots in real-world environments and achieve measurable economic returns.
• Evaluate FSD Subscription Growth: Monitor whether paid FSD customers continue growing and whether the attach rate on new vehicles remains above 55%, validating the software subscription thesis.
• Assess Capital Efficiency: Determine whether Tesla's capital expenditure generates returns that justify the $25 billion-plus annual investment, or whether the company is burning cash on speculative bets.

The Optimus story is ultimately about execution and timing. Tesla has the manufacturing expertise and financial resources to build humanoid robots at scale, but it has not yet demonstrated the ability to do so profitably or on schedule. Competitors are moving faster in some respects, and the market is punishing Tesla's current margins while waiting for a robotics future that may take years to materialize. For investors, the question is not whether Optimus will eventually be valuable, but whether Tesla can survive the transition period with enough capital and credibility intact to reach that destination.